Spots Global Cancer Trial Database for rilvegostomig
Every month we try and update this database with for rilvegostomig cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | NCT04541108 | Solid Tumor | Rilvegostomig Volrustomig Sabestomig Pembrolizumab | 18 Years - | Presage Biosciences | |
| Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | NCT04379596 | Gastric Cancer | Fluorouracil (5... Capecitabine Durvalumab Oxaliplatin Trastuzumab Trastuzumab der... Cisplatin Pembrolizumab Volrustomig Rilvegostomig | 18 Years - 130 Years | AstraZeneca | |
| Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | NCT05702229 | Gastric Cancer | Rilvegostomig Volrustomig FOLFOX XELOX AZD7789 AZD0901 5-Fluorouracil Capecitabine | 18 Years - | AstraZeneca | |
| PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC | NCT06366451 | Head and Neck S... | Rilvegostomig Volrustomig Sabestomig Pembrolizumab | 18 Years - | Presage Biosciences | |
| Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | NCT04541108 | Solid Tumor | Rilvegostomig Volrustomig Sabestomig Pembrolizumab | 18 Years - | Presage Biosciences | |
| Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | NCT05702229 | Gastric Cancer | Rilvegostomig Volrustomig FOLFOX XELOX AZD7789 AZD0901 5-Fluorouracil Capecitabine | 18 Years - | AstraZeneca | |
| Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | NCT04541108 | Solid Tumor | Rilvegostomig Volrustomig Sabestomig Pembrolizumab | 18 Years - | Presage Biosciences | |
| Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | NCT05775159 | Hepatocellular ... Biliary Tract C... | Volrustomig Bevacizumab Lenvatinib Rilvegostomig Gemcitabine Cisplatin | 18 Years - | AstraZeneca | |
| Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | NCT05702229 | Gastric Cancer | Rilvegostomig Volrustomig FOLFOX XELOX AZD7789 AZD0901 5-Fluorouracil Capecitabine | 18 Years - | AstraZeneca | |
| Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | NCT04379596 | Gastric Cancer | Fluorouracil (5... Capecitabine Durvalumab Oxaliplatin Trastuzumab Trastuzumab der... Cisplatin Pembrolizumab Volrustomig Rilvegostomig | 18 Years - 130 Years | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
